US EditionPublished • loading... • Updated
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
Mike Sibley brings over 20 years of biopharmaceutical experience to lead Neurocrine's neuropsychiatry sales and marketing, focusing on the INGREZZA franchise.
- On October 6, 2025, Neurocrine Biosciences, Inc. revealed that Mike Sibley will lead its Neuropsychiatry franchise in San Diego as the new Senior Vice President and General Manager.
- Neurocrine chose Sibley for his extensive background in commercial roles within the biopharma sector, totaling over two decades, as well as his recent leadership positions at Sanofi.
- Sibley will lead sales and marketing efforts for products such as INGREZZA, drawing on his extensive background at companies including Sanofi, Galderma, as well as previous experience in both the banking and healthcare industries.
- Eric Benevich, Chief Commercial Officer, praised Sibley for his proven leadership abilities and successful history of managing effective sales and marketing teams that achieve strong results.
- With this appointment, Neurocrine aims to further advance its neuropsychiatry product pipeline and continue delivering treatments to patients with significant needs.
Insights by Ground AI
19 Articles
19 Articles
Hanford Sentinel+18 Reposted by 18 other sources
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years…
Coverage Details
Total News Sources19
Leaning Left1Leaning Right0Center8Last UpdatedBias Distribution89% Center
Bias Distribution
- 89% of the sources are Center
89% Center
11%
C 89%
Factuality
To view factuality data please Upgrade to Premium
